Immunomedics (IMMU) – Major News
-
Gilead Sciences (GILD) to Acquire Immunomedics (IMMU) for $21 Billion
-
Gilead (GILD) Near Deal to Acquire Immunomedics (IMMU) for More than $20B - WSJ
-
Immunomedics (IMMU) Phase 3 ASCENT Study of TRODELVY in Previously-Treated Patients with mTNBC Met Primary Endpoint
-
Immunomedics (IMMU) Tops Q1 EPS by 1c
-
Immunomedics (IMMU) Confirms FDA Granted Accelerated Approval for Trodelvy in Previously-Treated Metastatic TNBC
-
Immunomedics (IMMU) Misses Q4 EPS by 4c
-
Immunomedics (IMMU) Misses Q3 EPS by 9c
-
Immunomedics (IMMU) Misses Q2 EPS by 50c
-
Immunomedics (IMMU) Reports Q1 Loss of $0.34
-
Immunomedics (IMMU) Misses Q4 EPS by 46c
-
Immunomedics (IMMU) Misses Q3 EPS by 6c
-
Immunomedics (IMMU) Reports Q2 Loss of $0.02
-
Immunomedics (IMMU) Enters Royalty Funding and Stock Purchase Agreements with Royalty Pharma Worth $250M
-
Immunomedics (IMMU) Misses Q1 EPS by 86c
-
Immunomedics (IMMU) Misses Q4 EPS by 36c, Miss on Revenues
-
Immunomedics (IMMU) Announces $125M Private Placement of Convertible Preferred Stock; Outlines Strategic Steps to Drive Stockholder Value; CEO to Step Down
-
Seattle Genetics (SGEN) and Immunomedics (IMMU) Sign Global License Agreement for Sacituzumab Govitecan (IMMU-132)
-
Immunomedics (IMMU) Misses Q1 EPS by 3c
-
Immunomedics (IMMU) Misses Q4 EPS by 6c
-
Immunomedics (IMMU) Misses Q3 EPS by 2c
-
Immunomedics (IMMU) to Terminate Phase 3 PANCRIT-1 w/ 90Y in Metastatic Pancreatic Cancer
-
Immunomedics (IMMU) Misses Q2 EPS by 1c
-
Immunomedics (IMMU) Misses Q1 EPS by 2c
-
Immunomedics (IMMU) Reports In-Line Q4 Loss of 13c/Share
-
UCB's Phase 3 Trial for Epratuzumab in Systemic Lupus Erythematosus Did Not Meet Primary Endpoint (IMMU)
-
Immunomedics, Inc. (IMMU) Misses Q4 EPS by 1c
-
Immunomedics, Inc. (IMMU) Reports In-Line Q2 Loss of 10c/Share
-
Immunomedics, Inc. (IMMU) Posts Q4 Loss of 9c/Share
-
Immunomedics, Inc. (IMMU) Swings to Q3 Profit
-
Immunomedics, Inc. (IMMU) Posts Mixed Q2 Results
-
Immunomedics, Inc. (IMMU) Misses Q4 EPS by 1c
-
Immunomedics, Inc. (IMMU) Posts Q1 Loss of 10c/Share
-
Immunomedics, Inc. (IMMU) Trumps Q2 EPS, Revenue Views
-
Immunomedics, Inc. (IMMU) Posts Narrower than Expected Q1 Loss
-
Immunomedics, Inc. (IMMU) Reports Q4 EPS of 3c
-
Immunomedics, Inc. (IMMU) Reports Q1 EPS Loss of $0.10, Misses Consensus by 2c
-
Immunomedics (IMMU) Posts Wider-Than-Expected Q1 Loss; Revs Beat
-
Immunomedics (IMMU) reports Q4 EPS of 1c
-
Immunomedics Inc. (IMMU) Posts Q3 EPS of $0.05, Beats by 7c
-
Immunomedics (IMMU) Reports Q2 EPS of $0.01
-
Immunomedics (IMMU) Reports Inline Q4 Results
-
Immunomedics (IMMU) Tops Q1 View By 3c
-
Immunomedics (IMMU) Reports Q1 Loss of $0.03
Back to IMMU Stock Lookup